OmniAb, Inc. Warrant
OABIWStock
$0.08
Market Cap—
P/E—
Div yield—
Beta1.68
Price Chart
Favorite Metrics
Price vs S&P 500 (4W)23.65%
VGM Score10.90
Industry Peers — R&D — Physical Sciences(15)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OABIWOmniAb, Inc. Warrant | — | — | F | $0.08 |
| IQVIQVIA Holdings Inc. | C | C | B | $210.49 |
| INCYIncyte Genomics Inc | C | A | B | $116.65 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | $537.92 |
| ICLRIcon Plc | C | C | B | $170.00 |
| CRLCharles River Laboratories International, Inc. | D | D | B | $229.16 |
| ABSIAbsci Corporation Common Stock | F | F | A | $8.23 |
| NRCNRC Health Common Stock | D | D | B | $21.94 |
| OABIOmniAb, Inc. Common Stock | D | C | B | $2.04 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | $1.35 |
| ONMDOneMedNet Corp Class A Common Stock | D | C | C | $0.69 |
About
OmniAb Inc develops proprietary antibody discovery technologies utilizing genetically engineered transgenic animals—OmniRat, OmniMouse, and OmniChicken—that produce fully human therapeutic antibodies optimized through in vivo affinity maturation. The company's platform enables rapid and efficient discovery of high-quality antibodies across diverse disease indications. By reducing development timelines while enhancing therapeutic quality, OmniAb accelerates the path from discovery to clinical application.